First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Clinical Activity of MRT-2359 + Enzalutamide Combo in Heavily Pretreated Metastatic CRPC Patients with Androgen Receptor Mutations Announced December 22, 2025
FDA approves AKEEGA® for BRCA2m metastatic CSPC with 54% reduction in disease progression vs SOC December 15, 2025
Encouraging Efficacy and Safety Profile from Ongoing Ph 1 Trial for JANX007 in mCRPC Announced December 9, 2025
Statistical analysis of primary efficacy endpoints in Ph 2 trial conducted of MCS-8 (PCP) in prostate cancer completed November 24, 2025
Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC October 29, 2025
US FDA Priority Review for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in BRCA-mutated metastatic CSPC October 21, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Positive Interim Efficacy Analysis of Ph 2 Trial of ENV105 in Advanced Prostate Cancer with Median PFS of Over One Year Announced September 23, 2025
Enrollment of Ph 1 TRE-515 Dose Escalation Trial for Patients with Solid Tumors Completed September 16, 2025
FDA approved CAMCEVI ETM long-acting injectable formulation for advanced prostate cancer September 3, 2025
VantAI and Halda Therapeutics Forge Alliance to Discover Next-Generation RIPTAC Medicines August 26, 2025
Discovery research reduced to support registrational trials for ORIC-944 and ORIC-114 August 19, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers August 19, 2025
German federal authority approves CTA to initiate Ph 1/2a trial of CC-38 in patients with metastatic CRC and metastatic prostate cancer August 19, 2025
FDA Clears IND for KTX-2001 in metastatic CRPC; Clinical Trial Collaboration with Bayer for Supply of Darolutamide announced August 11, 2025
ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha RLTs and Expand Manufacturing and Supply Chain Infrastructure August 5, 2025
Positive Safety Results from Ph 2 Trial of ENV-105 in Advanced Prostate Cancer Announced July 23, 2025
Nubeqa™ (darolutamide) receives EU approval for patients with metastatic HSPC based on positive results from the pivotal Ph 3 ARANOTE trial July 23, 2025
